These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 10970686)

  • 41. PET in testicular cancer.
    Becherer A
    Methods Mol Biol; 2011; 727():225-41. PubMed ID: 21331937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas.
    Mikhaeel NG; Timothy AR; Hain SF; O'Doherty MJ
    Ann Oncol; 2000; 11 Suppl 1():147-50. PubMed ID: 10707798
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 18-fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging.
    Yen RF; Hung RL; Pan MH; Wang YH; Huang KM; Lui LT; Kao CH
    Cancer; 2003 Jul; 98(2):283-7. PubMed ID: 12872346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of FDG-PET/CT in suspected recurrence of breast cancer.
    Radan L; Ben-Haim S; Bar-Shalom R; Guralnik L; Israel O
    Cancer; 2006 Dec; 107(11):2545-51. PubMed ID: 17063499
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography.
    Pecking AP; Mechelany-Corone C; Bertrand-Kermorgant F; Alberini JL; Floiras JL; Goupil A; Pichon MF
    Clin Breast Cancer; 2001 Oct; 2(3):229-34. PubMed ID: 11899417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.
    Zimny M; Siggelkow W; Schröder W; Nowak B; Biemann S; Rath W; Buell U
    Gynecol Oncol; 2001 Nov; 83(2):310-5. PubMed ID: 11606090
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value].
    Müller J; Schrader AJ; Jentzmik F; Schrader M
    Urologe A; 2011 Mar; 50(3):322-7. PubMed ID: 21161157
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
    Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
    AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical outcomes of patients with nonseminomatous germ cell tumours and negative postchemotherapy positron emission tomography.
    Buchler T; Simonova K; Fencl P; Jarkovsky J; Abrahamova J
    Cancer Invest; 2012 Jul; 30(6):487-92. PubMed ID: 22506657
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 18F-FDG PET/CT impact on testicular tumours clinical management.
    Ambrosini V; Zucchini G; Nicolini S; Berselli A; Nanni C; Allegri V; Martoni A; Rubello D; Cricca A; Fanti S
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):668-73. PubMed ID: 24265073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients.
    Moore HG; Akhurst T; Larson SM; Minsky BD; Mazumdar M; Guillem JG
    J Am Coll Surg; 2003 Jul; 197(1):22-8. PubMed ID: 12831920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
    Graeber GM; Gupta NC; Murray GF
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
    Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
    Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Belhocine T; Hustinx R; Rigo P; Fillet G
    Ann Oncol; 2003 Jan; 14(1):123-30. PubMed ID: 12488304
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utility of 18-fluorodeoxyglucose positron emission/computed tomography in the management of recurrent colorectal cancer.
    Liong SY; Kochhar R; Renehan AG; Manoharan P
    ANZ J Surg; 2012 Oct; 82(10):729-36. PubMed ID: 22989147
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA.
    Sarikaya I; Bloomston M; Povoski SP; Zhang J; Hall NC; Knopp MV; Martin EW
    World J Surg Oncol; 2007 Jun; 5():64. PubMed ID: 17555577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.
    Treglia G; Sadeghi R; Annunziata S; Caldarella C; Bertagna F; Giovanella L
    Biomed Res Int; 2014; 2014():852681. PubMed ID: 24963486
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.
    Kahn D; Follett KA; Bushnell DL; Nathan MA; Piper JG; Madsen M; Kirchner PT
    AJR Am J Roentgenol; 1994 Dec; 163(6):1459-65. PubMed ID: 7992747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence.
    Chen YK; Hsieh DS; Liao CS; Bai CH; Su CT; Shen YY; Hsieh JF; Liao AC; Kao CH
    Anticancer Res; 2005; 25(6C):4719-25. PubMed ID: 16334166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.